MIMETAS in 6 m€ EU alliance to fight Parkinson’s disease

MIMETAS in 6 m€ EU alliance to fight Parkinson’s disease

Parkinson’s disease (PD) is a progressive neurological disorder that is increasingly prevalent with age. After Alzheimer’s disease, PD is the second most common neurodegenerative disease and its prevalence will continue to grow as the population ages. More than one million people with PD live in Europe today and this number is forecast to double by 2030. Currently, the associated European cost estimated at €13.9 billion annually.

With the start of SysMedPD on December 1, 2015, MIMETAS takes part in a new EU research project that sets out to further explore and identify novel drug candidates capable of slowing down the progression of neurodegeneration in the subset of PD patients with overt mitochondrial dysfunction. The research during SysMedPD will specifically focus on monogenic forms of PD that involve mitochondrial abnormalities as a primary or secondary phenomenon, which is estimated to account for 10% to 20% of the total number of PD patients corresponding to 1-2 million people.

Equipped with a budget of €5.9 million, the SysMedPD consortium’s objectives are to leverage national but especially European investments in the systems biomedicine sector, to improve means for PD detection and therapy development by developing tools and approaches, and to commercialize the project results so the society as a whole can benefit from the results. Although there are several existing investments in the systems biomedicine in the EU, many of those investments have not yet been leveraged due to the high costs of assays. However, screenings of large compound libraries derived from nature and synthetic chemistry, are crucial on the path to identifying novel drugs. This is where SysMedPD comes in: ‘Current therapies of Parkinson’s disease are only symptomatic. We are very excited about the SysMedPD consortium because its goal is to develop new drugs based on the mechanisms of PD. This requires interdisciplinary cooperation from clinicians to engineers to computational biologists’, explains Rudi Balling, Coordinator of SysMedPD and Director of the Luxembourg Centre for Systems Biomedicine.

As PD patients are five times more likely to require nursing home care and this care costs about five times more than the average nursing home care, successful development of drugs slowing PD-progression would not only lead to an increase in the quality of life of patients, but will also lead to health care cost savings. There will be a subsequent economic impact for companies developing drugs for PD, as the miniaturization of cell culture and metabolomics assay developed within SysMedPD will reduce the associated costs.

The SysMedPD partners can build on the scientific expertise of an outstanding consortium of complementary academic groups as well as biopharmaceutical companies with longstanding expertise in the field of mitochondrial medicine and drug testing.

EU flag
SysMedPD has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 668738.

Related content

<a href="/mimetas-news-archive">back to overview</a>

Related Articles